Assertio Holdings Inc banner
A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 18.02 USD -0.06% Market Closed
Market Cap: $116.4m

Assertio Holdings Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Assertio Holdings Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Free Cash Flow
-$28.2m
CAGR 3-Years
N/A
CAGR 5-Years
16%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Free Cash Flow
$19.7B
CAGR 3-Years
7%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Free Cash Flow
$12.8B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
26%
Pfizer Inc
NYSE:PFE
Free Cash Flow
$9.1B
CAGR 3-Years
-30%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Free Cash Flow
$12.4B
CAGR 3-Years
-6%
CAGR 5-Years
16%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Free Cash Flow
$6B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
16%
No Stocks Found

Assertio Holdings Inc
Glance View

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
50.33 USD
Undervaluation 64%
Intrinsic Value
Price $18.02
A

See Also

What is Assertio Holdings Inc's Free Cash Flow?
Free Cash Flow
-28.2m USD

Based on the financial report for Dec 31, 2025, Assertio Holdings Inc's Free Cash Flow amounts to -28.2m USD.

What is Assertio Holdings Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
16%

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett